|Healthcare Review: StemCells , CollabRx Inc, Pfizer, NuVasive Are Notable Movers|
|By Staff and Wire Reports|
|Thursday, 04 October 2012 13:17|
Following are the notable movers in the sector at mid day on Thursday:
StemCells, Inc.(NASDAQ:STEM) shares gained 5.21% to $2.22 after the company announced that the first patient in its Phase I/II clinical trial in dry age-related macular degeneration (AMD) has been enrolled and transplanted. The trial is designed to evaluate the safety and preliminary efficacy of the Company's proprietary HuCNS-SC(R) product candidate as a treatment for dry AMD, and the patient was transplanted with the cells yesterday at the Retina Foundation of the Southwest in Dallas, Texas, one of the leading independent vision research centers in the United States.
CollabRx Inc. (NASDAQ:CLRX) shares surged 84.13% to $6.98 after the company announced a multi-year partnership agreement with Life Technologies Corporation for development and commercialization of CollabRx technology and content resources to be used in conjunction with Life Technologies’ global cancer diagnostics development and its laboratory developed test services business.
Pfizer Inc. (NYSE:PFE) stock increased 0.08% to $25.34 after the company announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age. These data support a recent regulatory submission to expand the indication of Prevenar 13 in the European Union to include adults between 18 and 49 years old, and will be used to support similar planned submissions in other countries around the world in the future.
NuVasive, Inc. (NASDAQ:NUVA) stock plummeted 33.69% to $15.01 after the company said that it now expects third quarter revenue to be about $147 million, which is below the company's previous comments that suggested flat sequential revenue growth compared to $154.4 million in the second quarter. Analysts currently expect the company to post revenue of $153.62 million for the third quarter.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares climbed 4.44% to $2.59. The company, last month, announced the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin, in patients with Parkinson's disease psychosis. The company expects top-line results from the trial by the end of November. Pimavanserin is ACADIA's proprietary small molecule that acts selectively as an antagonist/inverse agonist on serotonin 5-HT2A receptors and is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis.